Highlights of NCCN/AUA Guidelines 2024
Siamak Daneshmand, MD, covers recent updates in bladder cancer guidelines, focusing on the 2024 NCCN and AUA recommendations.
Read MoreSelect Page
Posted by Siamak Daneshmand, MD | Apr 2025
Siamak Daneshmand, MD, covers recent updates in bladder cancer guidelines, focusing on the 2024 NCCN and AUA recommendations.
Read MorePosted by Edwin M. Posadas, MD, FACP | Apr 2025
Edwin M. Posadas, MD, FACP, explores prostate cancer diagnostics and treatment, emphasizing biomarkers and liquid biopsy technologies.
Read MorePosted by Alexandra Drakaki, MD, PhD | Mar 2025
Alexandra Drakaki, MD, PhD, explores circulating tumor DNA in bladder cancer, highlighting its potential as a biomarker.
Read MorePosted by Andre Abreu, MD | Jan 2025
Andre Abreu, MD, delves into energy modalities for focal therapy in prostate cancer, presented with a comprehensive and practical approach. This 16-minute presentation explores multiple energy options, including cryoablation, high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE), laser ablation, and microwave ablation. Dr. Abreu emphasizes the importance of aligning energy selection with institutional expertise and patient-specific factors.
Patient-specific considerations guide technology selection, including rectal wall thickness and proximity to critical structures. Transition zone lesions benefit from tools like aqua ablation, while anterior lesions present challenges for certain devices. The speaker emphasizes the need for personalized management, integrating oncologic characteristics with procedural capabilities.
Dr. Abreu optimistically frames the future of focal therapy, with ongoing trials like vapor ablation and the potential for low-dose radiation therapy combined with IRE promising advancements. He calls for practical recommendations and an invitation for ongoing exploration in the evolving field of prostate cancer management.
Read MorePosted by Robert E. Reiter, MD, MBA | Jan 2025
Robert E. Reiter, MD, MBA, highlights advances in molecular targeting and imaging in prostate cancer, with a focus on PSMA PET imaging. PSMA PET is expanding its role, particularly in identifying primary or secondary tumors when MRI results are negative or ambiguous. This application, under investigation in the Primary Two study, could reduce unnecessary biopsies and improve tumor detection.
In this 7-minute presentation, Dr. Reiter reviews PSMA-guided surgical resection using fluorescence or radioguidance to enhance precision. He asserts that this approach could reduce positive margins, optimize node removal, and support nerve-sparing techniques when appropriate, improving functional outcomes.
Reiter also discusses PSMA PET in oligometastatic disease, specifically the optimal treatment approach when few metastases are present. In addition, PSMA imaging is being explored in focal and radiation therapies, where it could provide a more accurate assessment of recurrence and treatment response; in advanced prostate cancer, PET could help identify resistant lesions for targeted radiotherapy.
Read More